Browse articles from EyeWorld.org related to medication. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Dry eye continues to be an important topic because of the many patients impacted and different ways it can present. Two cornea specialists highlighted some of the newer treatment options and how they are handling dry eye in their practice, including how they have updated their approach with experience.
For years, ophthalmologists had limited prescription options for patients with ocular surface disease. In the last decade, the number of available options has grown with several receiving approval in 2023. Two experts shared their thoughts and experiences with these new options.
A 2024 ASCRS Annual Meeting symposium featured quick-hit tips from glaucoma specialists. Panelists were asked to share a 1-minute pearl in a variety of categories and included Sarah Van Tassel, MD, Kuldev Singh, MD, MPH, Douglas Rhee, MD, Lorraine Provencher, MD, and Christopher Teng, MD, MBA.
One physician shared how switching out the typical top on a glaucoma medication for the Nanodropper Adaptor, a screw-on cap that delivers a smaller drop of the medication, has helped her glaucoma patients from a compliance standpoint.
Losartan is being studied as a potential treatment for corneal fibrosis and scarring. An ophthalmologist who has been conducting studies on the use of topical losartan spoke about the status of those studies, experience with off-label applications in human patients, and his thoughts about this option becoming more available.
➤ Positive topline data for travoprost implant ➤ Enrollment complete for dry AMD interventional trial ➤ European Commission approves new treatment for wet AMD and DME ➤ Interim results for first-in-human trial with new glaucoma implant ➤ Three non-antibiotic drugs identified to treat ocular infection ➤ ASCRS news and events
Durysta, the sustained-release bimatoprost implant, 10 mcg (Allergan), has been available with FDA approval in the U.S. market for a year now. EyeWorld spoke with two physicians who started offering it as an option to their patients to hear about their experience thus far.
A drop or pill that could forestall or even reverse cataract formation has been discussed and researched for years. It’s an especially attractive options for patients in developing countries where surgery can be less available or less safe.
EyeWorld spoke with several experts for a comprehensive overview of three novel glaucoma medications.
About 1 in 5 Americans use antidepressants or anti-anxiety medications. With that large percentage, ophthalmologists probably encounter patients daily who use or have used these medications.